MiMedx Group announced the elimination of its Chief Operating Officer position, a move that will cut annual operating expenses by roughly $40 million. The decision, made by CEO Joseph Capper, follows a review of the company’s business and corporate structure and reflects the slower‑than‑expected recovery of the wound‑care market after the Medicare reimbursement cut that took effect on January 1 2026.
Capper said the restructuring will allow the company to focus resources on its growing surgical business while maintaining profitability in the wound‑care segment. A one‑time restructuring charge of about $4 million is expected to hit the company in the second quarter of 2026, and the company will provide further commentary on the impact during its upcoming quarterly conference call.
The elimination of the COO role is a strategic shift aimed at streamlining operations and preserving cash flow as MiMedx navigates a challenging reimbursement environment. The move signals management’s intent to tighten costs and prioritize growth opportunities in the surgical segment, which has been performing strongly in recent quarters.
In Q4 2025, MiMedx reported wound‑care product sales of $79 million, up 28% year‑over‑year, and surgical sales of $39 million, up 25% year‑over‑year. The company’s CEO noted that the wound‑care market is recovering from the January 1st Medicare reimbursement reduction at a very slow rate, while the surgical business continues to flourish and warrants additional investments.
Capper said, "As we entered the new year, we kept the organization resourced in the event of a rapid recovery in the Wound market. Based on first quarter market behavior, it is clear the transition is happening at a more sluggish pace, and we must now make the requisite adjustments to our cost structure to ensure the future profitability of the business. As such, we have taken steps to reduce our annual operating expenses across the enterprise by approximately $40 million."
He also thanked former COO Ricci for her contributions, saying, "On behalf of the Board and management team, I want to thank Ricci for her innumerable contributions to MIMEDX and her exceptional leadership in helping to build and scale our operations."
The company’s strategy to eliminate the COO role and achieve $40 million in annualized savings is intended to strengthen its balance sheet and free capital for investment in the surgical segment, which has shown robust growth and higher margins. The one‑time $4 million restructuring charge reflects the costs of consolidating functions and streamlining the organization, and is expected to be fully absorbed in the second quarter of 2026.
Overall, the restructuring is a significant operational change that positions MiMedx to better navigate the headwinds in its core wound‑care market while capitalizing on the momentum in its surgical business. The company’s focus on cost discipline and strategic resource allocation underscores its commitment to sustaining profitability and supporting future growth.
revised_sentiment_rating":0} }
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.